Group 1 - Lisata Therapeutics, Inc. will report its financial results for the twelve months ended December 31, 2024, on February 27, 2025, after market close [1] - A conference call will be hosted at 4:30 p.m. Eastern time on the same day, with registration required for participation [2] - A live webcast of the call will be available on Lisata's website and will be accessible for replay for 12 months after the call [3] Group 2 - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases, with its lead product candidate, certepetide, designed to enhance the targeting of anti-cancer drugs [4] - The company has established significant commercial and R&D partnerships based on its CendR Platform® technology and anticipates announcing multiple milestones over the next 1.5 years [4] - Lisata expects its projected capital to fund operations into the second quarter of 2026, covering anticipated data milestones from ongoing and planned clinical trials [4]
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025